Reference range for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET

No prior work had resolved the expected range of scan-to-scan fluctuations for normal tissue baselines in oncological imaging. Clinicians often rely on blood-pool or liver activity to normalize tumor measurements during treatment monitoring. That uncertainty drove the need for a standardized reference range to interpret longitudinal PET data accurately. Prior research has shown that standardized uptake value metrics are susceptible to various technical and biological artifacts. This gap motivated the current investigation into how these baseline values shift between repeated examinations. Understanding these fluctuations is vital for distinguishing genuine disease progression from inherent measurement noise. Researchers previously lacked a clear benchmark for assessing the stability of these reference tissues over time. Establishing these limits provides a necessary foundation for reliable qualitative and quantitative tumor response assessment.

The aim of this study was to document the normal intrapatient range of scan-to-scan variation in blood-pool and liver uptake. Researchers sought to identify clinical factors that might adversely affect the spread of these measurements. This investigation addresses the need for a stable baseline to validate semiquantitative tumor response assessments. By defining these normal fluctuations, the team provides a benchmark for interpreting longitudinal PET data. The study specifically examines whether common clinical variables influence the consistency of these reference tissue measurements. This work addresses the uncertainty surrounding how much variation is expected in repeated imaging sessions. Establishing these limits is necessary for clinicians to distinguish between true disease progression and normal physiological noise. The motivation stems from the requirement for reliable quantitative metrics in oncology treatment monitoring.

The review approach involved a retrospective analysis of 132 oncology patients who underwent two consecutive PET/CT examinations. Researchers maintained uniform patient preparation, tracer administration, and image reconstruction protocols throughout the study period. Mean uptake metrics were calculated from two-dimensional regions of interest placed within the aortic arch and right hepatic lobe. The team compared data from the first and second visits to determine the extent of scan-to-scan fluctuation. Statistical assessments included calculating the mean and standard deviation of these differences to establish gaussian distributions. Subgroup analyses examined potential influences from cancer diagnosis and chemotherapy status on the observed uptake shifts. The investigators evaluated whether specific clinical factors systematically altered the spread of these variations. This systematic approach ensured that the resulting reference ranges reflected consistent and reproducible physiological behavior.

The strongest finding indicates that the reference range for intrapatient variation is -0.8 to 0.9 for blood-pool and -0.9 to 1.1 for liver activity. Mean blood-pool uptake was 1.55 at the first visit and 1.58 at the second, showing no statistical difference. Liver uptake increased from a mean of 2.17 to 2.29, which reached statistical significance with a p-value of 0.005. Variation in both tissue types followed a gaussian distribution pattern across the patient cohort. The blood-pool variation had a mean of 0.03 with a standard deviation of 0.42. Liver variation exhibited a mean of 0.12 and a standard deviation of 0.50. No clinical factors were identified that systematically increased the spread of these variations. These results demonstrate that while liver activity may shift slightly, the overall fluctuation remains within a predictable range.

The authors propose that the established reference ranges provide a benchmark for interpreting longitudinal PET data. Synthesis and implications suggest that clinicians should account for these normal fluctuations when evaluating tumor response. The observed shift in liver activity between visits likely stems from the initiation of chemotherapy protocols. No clinical or technical factors were found to systematically increase the spread of these variations. These findings imply that blood-pool and liver measurements remain relatively stable across repeated imaging sessions. The study provides a quantitative framework for defining significant changes in tracer uptake. Future assessments of tumor response should utilize these calculated limits to avoid misinterpreting normal physiological noise. These results offer a practical guide for clinicians to differentiate between therapeutic effects and inherent scan-to-scan variability.